Inhaled corticosteroids for cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 10, 2014, Pages

  Balfour Lynn, Ian M ^a   Welch, Karen ^b  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PLACEBO; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID;

ADOLESCENT; ADRENAL INSUFFICIENCY; ADULT; AGE; ANTIBIOTIC THERAPY; BRONCHUS HYPERREACTIVITY; CATARACT; CHILD; CUSHINGOID SYNDROME; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG USE; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HOSPITAL ADMISSION; HUMAN; INTERMETHOD COMPARISON; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OPEN STUDY; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN DISEASE; SURVIVAL; SYSTEMATIC REVIEW; THRUSH; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; CYSTIC FIBROSIS; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; YOUNG ADULT;

EID: 84921952294     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001915.pub4     Document Type: Review

References (89)

1. Eichler I, Wojnarowski C, Frischer T, Renner S, Koller DY, Gotz M. Inhaled corticosteroids suppress increased eosinophil cationic protein concentration in patients with cystic fibrosis [abstract]. Pediatric Pulmonology 1995;Suppl 12:326. [CFGD Register: IB14a]
2. Wojnarowski C, Gotz M, Eichler HG, Frischer T, Koller DY, Eichler I. Topical steroid act anti-inflammatorily by patients with cystic fibrosis [abstract]. Monatsschrift Fur Kinderheilkunde. 1995; Vol. 143:218. [CFGD Register: IB14c]
3. Wojnarowski C, Gõtz M, Eichler HG, Frischer T, Renner S, Koller DY, et al. Inhaled corticosteroids suppress inflammation in patients with cystic fibrosis [abstract]. 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:Poster P98. [CENTRAL: 291657; CFGD Register: IB14b; CRS: 5500100000001649]
4. De Boeck K, De Baets F, Malfroot A, Desager K, Mouchet F, Proesmans M. Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients?. European Journal of Pediatrics 2007;166(1):23-8. [CFGD Register: IB49]
5. Schmidt J, Davidson AGF, Seear M, Wong LTK, Peacock D, Gravelle A, et al. Is the acquisition of pseudomonads in cystic fibrosis patients increased by use of inhaled corticosteroids? Unexpected results from a double blind placebo controlled study [abstract]. Pediatric Pulmonology 1997;Suppl 14:293. [CFGD Register: IB18]
6. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, et al. CF WISE - Multicentre randomised controlled trial of withdrawal of inhaled corticosteroids [abstract]. Pediatric Pulmonology 2005;40(Suppl 28):123-4. [CFGD Register: IB48a]
7. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. American Journal of Respiratory and Critical Care Medcine 2006;173(12):1356-62. [CFGD Register: IB48b]
8. Schiotz P, Jorgensen M, Winge Flensborg E, Fero O, Husby S, Hoiby N, et al. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of CF patients: influence of local steroid treatment [abstract]. Proceedings of the 11th European Cystic Fibrosis Conference; 1982; Brussels. 1982:51. [CFGD Register: IB1b]
9. Schiotz PO, Jorgensen M, Flensborg EW, Faero O, Husby S, Hoiby N, et al. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatrica Scandinavica 1983;72(2):283-7. [CENTRAL: 30682; CFGD Register: IB1a; CRS: 5500100000000167; PUBMED: 6340415]
10. Bisgaard H, Nielson K H, Sov M, Mosfeldt E, Bjerre B, Pedersen S, et al. Inhaled steroid treatment of CF patients with chronic pseudomonas aeruginosa (P.a.) lung infection [abstract]. Pediatric Pulmonology 1994;18(Suppl 10):395. [CFGD Register: IB12a]
11. Bisgaard H, Pedersen SS, Nielsen KG, Skov M, Laursen EM, Kronborg G, et al. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary pseudomonas aeruginosa infection. American Journal of Respiratory and Critical Care Medicine 1997;156(4 Pt 1):1190-6. [CFGD Register: IB12c]
12. Bisgaard H, Petersen SS, Nielsen KG. Topical steroid treatment ameliorate lung pathophysiology of patients with cystic fibrosis and chronic pseudomonas AER [abstract]. European Respiratory Journal 1996;9(Suppl):174S. [CFGD Register: IB12b]
13. van Haren EH, Lammers JW, Festen J, Heijerman HG, Groot CA, van Herwaarden CL. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respiratory Medicine 1995;89(3):209-14. [CFGD Register: IB9]
14. Dauletbaev N, Viel K, Behr J, Loitsch S, Buhl R, Wagner TOF, Bargon J. Effects of short-term inhaled fluticasone on oxidative burst of sputum cells in cystic fibrosis patients. European Respiratory Journal 1999;14(5):1150-5. [CFGD Register: IB26]
15. Hayes J, Cosgrave C, O'Connor C, FitzGerald M. The effect of high dose inhaled corticosteroids on levels of sputum of plasma elastase and IL8 in patients with mild cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995;151(4 Suppl):A248. [CFGD Register: IB8a]
16. Hayes J, Cosgrave C, O'Connor C, FitzGerald MX. The effect of high dose inhaled corticosteroids on levels of sputum or plasma elastase IL-8 in patients with mild cystic fibrosis. Irish Journal of Medical Science 1995;164(2):165. [CFGD Register: IB8b]
17. Nikolaizik WH, Schoni MH. Effect of inhaled corticosteroids on lung function of cystic fibrosis patients - a prospective study [abstract]. European Respiratory Journal 1994;7:430S. [CFGD Register: IB15b]
18. Nikolaizik WH, Schoni MH. Pilot study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis. Journal of Pediatrics 1996;128(2):271-4. [CFGD Register: IB15c]
19. Schöni MH, Nikolaizik. Parallel group study to assess the effect of inhaled corticosteroids on lung function in patients with cystic fibrosis [abstract]. Israel Journal of Medical Sciences 1996;32(Suppl):S190. [CENTRAL: 291577; CFGD Register: IB15a; CRS: 5500100000001585]
20. Uyan ZS, Unluguzel G, Haklar G, Cakir E, Oktem S, Ersu R, et al. The effect of inhaled steroids on bronchial hyperreactivity, oxidative status, clinical and inflammatory parameters in patients with cystic fibrosis [abstract]. Journal Cystic Fibrosis 2008;7(Suppl 2):S68. [CFGD Register: IB50a]
21. Uyan ZS, Unluguzel G, Haklar G, Cakir E, Oktem S, Ersu R, et al. The effect of inhaled steroids on bronchial hyperreactivity, oxidative status, clinical and inflammatory parameters in patients with cystic fibrosis [abstract]. Proceedings of European Respiratory Society Annual Congress; 2007 Sep 15-19; Stockholm, Sweden. 2007:646s. [CFGD Register: IB50b]
22. Nieman R, Williams S, Maden C, Knight R, Hodson M. A double-blind placebo-controlled study comparing the effects of the inhaled corticosteroid fluticasone propionate 500 mcg BID with placebo in adults with cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine 1996;153:A72. [CFGD Register: IB16]
23. Balfour-Lynn I, Klein N J, Dinwiddie R. Randomised controlled trial of inhaled corticosteroids (fluticasone propionate) in cystic fibrosis. Archives of Disease in Childhood 1997;77(2):124-30. [CFGD Register: IB17d]
24. Balfour-Lynn I, Klein N J, Dinwiddie, R. Sputum Interleukin-10 in Cystic Fibrosis [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):324. [CFGD Register: IB17b]
25. Balfour-Lynn IM, Klein NJ, Dinwiddie R. Trial of inhaled corticosteroids (Fluticasone Propionate) in children with cystic fibrosis(CF) [abstract]. Israel Journal of Medical Sciences 1996;32(Suppl):S190. [CENTRAL: 291194; CFGD Register: IB17a; CRS: 5500100000001273]
26. Balfour-Lynn IM, Klein NJ, Laverty A, Dinwiddie R. Effect of inhaled corticosteroids on airway nitric oxide levels in children with CF [abstract]. Pediatric Pulmonology 1996;Suppl 13:324. [CFGD Register: IB17c; CRS: 5500100000010644]
27. McElrea MS, O'Donnell SR, Francis PW. The effects of high-dose inhaled beclomethasone dipropionate (BDP) on lung function and sputum albumin in children with cystic fibrosis (CF) [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):301. [CFGD Register: IB31]
28. Bessaci K, Milliot M, Zahm J, Vilprey M, Coraux C, Mauran P, et al. Effects of inhaled association of salmeterol-fluticasone propionate on lung and epithelial cell functions in cystic fibrosis children [abstract]. Pediatric Pulmonology 2008;43(Suppl 31):384. [CFGD Register: IB51b]
29. Bessaci K, Milliot M, Zahm JM, Coraux C, Mauran P, Vitry F, et al. Effects of inhaled salmeterol-fluticasone propionate on lung and epithelial cell functions in cystic fibrosis children: a double blind crossover study [abstract]. Journal of Cystic Fibrosis 2008;7(Suppl 2):S66. [CFGD Register: IB51a]
30. Wojtczak HA, Kerby GS, Wagener JS, Copenhaver SC, Gotlin RW, Riches DW, et al. Beclomethasone dipropionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatric Pulmonology 2001;32(4):293-302.
31. Wotjczak HA, Wagener JS, Kerby G, Gotlin R, Accurso F. Effect of inhaled beclomethasone dipropionate on airway inflammation in children with cystic fibrosis [abstract]. Pediatric Pulmonology 1996;22(Suppl 13):323-4.
32. WojtczaK HA, Wagener JS, Sontag MK, Accurso FJ. Bronchoalveolar lavage assessment of airway delivery of fluticasone propionate via pressurised metered dose inhaler in infants and young children with cystic fibrosis. Pediatric Pulmonology 1998;S19:341. [CFGD Register: IB22a]
33. Wojtczak HA, Sontag MK, Wagener JS, Accurso FJ. Inhaled corticosteroid treatment in infants and young children with cystic fibrosis [abstract]. Pediatric Pulmonology 1999;28(Suppl 19):105-6. [CFGD Register: IB22b]
34. Kapustina T, Fedorova V, Voronkova A, Kapranov N. Long-term treatment with corticosteroids and bone mineral density in patients with cystic fibrosis [abstract]. European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:214s. [CFGD Register: IB94]
35. Association of the British Pharmaceutical Industry. Compendium of Data Sheets and Summaries of Product Characteristics 1999-2000. London: Datapharm Publications Ltd, 1999.
36. Armstrong DS, Greenwood K, Carzino JB, Olinsky A, Phelan PD. Lower respiratory infection and inflammation in infants with newly-diagnosed cystic fibrosis. BMJ 1995;310(6994):1570-72.
37. Balfour-Lynn IM, Dezateux C. Corticosteroids and ibuprofen in cystic fibrosis (letter). Thorax 1999;54(7):657.
38. Balfour-Lynn IM, Elborn JS. "CF asthma": what is it and what do we do about it?. Thorax 2002;57:742-8.
39. Balfour-Lynn IM. Anti-inflammatory approaches to cystic fibrosis airways disease. Current Opinion in Pulmonary Medicine 2007;13:522-8.
40. Balfour-Lynn IM. Personal communication with UK CF Trust and CFF October 2008.
41. Balough K, McCubbin M, Weinberger M, Smits W, Ahrens R, Fick R. The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatric Pulmonology 1995;20(2):63-70.
42. Barnes PJ, Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. American Review of Respiratory Disease 1993;148(4 Pt 2):S1-26.
43. Booth H, Richmond I, Ward C, Gardiner PV, Harkawat R, Walters EH. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine 1995;152(1):45-52.
44. Burdon JG, Cade JF, Sutherland PW, Pain MC. Cystic fibrosis and bronchial hyperreactivity: concomitant defects or cause and effect?. Medical Journal of Australia 1980;2(2):77-8.
45. Calpin C, Macarthur C, Stephens D, Feldman W, Parkin PC. Effectiveness of prophylactic inhaled steroids in childhood asthma: a systemic review of the literature. Journal of Allergy and Clinical Immunology 1997;100(4):452-7.
46. Cheng K, Ashby, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database of Systematic Reviews 1999, Issue 4. [DOI: 10.1002/14651858.CD000407.pub2]
47. Djukanovic R, Wilson JW, Britten KM, Wilson SI, Walls AF, Roche WR, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. American Review of Respiratory Disease 1992;145(3):669-74.
48. Drake AJ, Howells RJ, Shield JPH, Prendiville A, Ward PS, Crowne PC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ 2002;324(7345):1081-2.
49. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analysis involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
50. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. American Journal of Respiratory and Critical Care Medicine 2007;176(10):957-69.
51. Green RH, Brightling CE, Woltmann G, Parker D, Wardlaw AJ, Pavord ID. Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 2002;57(10):875-79.
52. Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. American Journal of Respiratory and Critical Care Medicine 2002;165(12):1592-6.
53. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
54. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008.
55. Hilliard TN, Balfour-Lynn IM. Anti-inflammatory agents a clinical perspective. In: Bush A editor(s). Progress in Respiratory Research Cystic Fibrosis. Basel: S Karger AG, 2005:187-94.
56. Khan TZ, Wagner JS, Bost T, Martinez J, Accurso FJ, Riches DW. Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 1995;151(4):1975-82.
57. Koch C, McKenzie SG, Kaplowitz H, Hodson ME, Harms HK, Navarro J, et al. International practice patterns by age and severity of lung disease in cystic fibrosis: data from the Epidemiologic Registry of Cystic Fibrosis (ERCF). Pediatric Pulmonology 1997;24(2):147-154.
58. Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. American Journal of Respiratory Cell and Molecular Biology 2004;31(4):377-81.
59. Konstan MW, Hilliard KA, Norvell EM, Berger M. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. American Journal of Respiratory and Critical Care Medicine 1994;150(2):448-54.
60. Konstan MW, Butler SM, Schidlow DV, Morgan WJ, Julius JR, Johnson CA, for the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies. Pediatric Pulmonology 1999;28(4):248-54.
61. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Archives of Internal Medicine 1999;159(9):941-55.
62. Macdessi JS, Randell TL, Donaghue KC, Ambler GR, Van Asperen PP, Mellis CM. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. Medical Journal of Australia 2003;178(5):214-6.
63. Main KM, Skov M, Sillesen IB, Dige-Petersen H, Muller J, Koch C, et al. Cushing's syndrome due to pharmacological interaction in a cystic fibrosis patient. Acta Pediatrica 2002;91(9):1008-11.
64. Minicucci L, Severi G, Cresta L, Giannattasio A, Lorini R, Haupt R. Impact of inhaled corticosteroids on the risk of early Pseudomonas aeruginosa acquisition in cystic fibrosis. Acta Paediatica 2003;92(6):684-7.
65. Mitchell I, Corey M, Woenne R, Krastins IR, Levison H. Bronchial hyperreactivity in cystic fibrosis and asthma. Journal of Pediatrics 1978;93(5):744-8.
66. Morgan WJ, Butler SM, Johnson CA, Colin AA, FitzSimmons SC, Geller DE, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatric Pulmonology 1999;28(4):231-41.
67. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease: national clinical guideline for management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; Vol. 59, issue Suppl 1.
68. Padman R, McColley SA, Miller DP, Konstan MW, Morgan WJ, Schechter MS, et al. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics 2007;119(3):e531-7.
69. Parmar JS, Howell T, Kelly J, Bilton D. Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis. Thorax 2002;57(8):749-50.
70. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Archives of disease in childhood 2001;85(4):330-4.
71. Patel H, Platt R, Lozano JM, Wang EEL. Glucocorticoids for acute viral bronchiolitis in infants and young children. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD004878.pub2]
72. Renkema TE, Schouten UP, Koeter GH Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest 1996;109(5):1156-62.
73. Russell G. The use of inhaled corticosteroids during childhood: plus ca change. Archives of Disease in Childhood 2004;89(10):893-5.
74. Schulz K, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. Journal of the American Medical Association 1995;273(5):408-12.
75. Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S. Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide. European Respiratory Journal 2002;20(1):127-33.
76. Smeeth L, Boulis M, Hubbard R, Fletcher AE. A population based case-control study of cataract and inhaled corticosteroids. British Journal of Opthalmology 2003;87(10):1247-51.
77. Taylor AV, Laoprasert N, Zimmerman D, Sachs MI. Adrenal suppression secondary to inhaled fluticasone propionate. Annals of Allergy, Asthma & Immunology 1999;83(1):68-70.
78. Tobin MJ, Maguire D, Keen D, Tempany E, Fitzgerald MX. Atopy and bronchial reactivity in older patients with cystic fibrosis. Thorax 1980;35(11):807-13.
79. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996;348(9019):27-9.
80. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Archives of Disease in Childhood 2002;87(6):457-61.
81. van Grunsven PM, van Schayck CP, Molema J, Akkermans RP, van Weel C. Effect of inhaled corticosteroids on bronchial responsiveness in patients with "corticosteroid naive" mild asthma: a meta-analysis. Thorax 1999;54(4):316-22.
82. Walters S. Association of cystic fibrosis adults (UK) Survey 1994-Analysis and Report. Cystic Fibrosis Trust 1995.
83. Walters S. Personal communication June 14 2001.
84. Weir DC, Burge PS. Effects of high dose inhaled beclomethasone dipropionate 750 micrograms and 1500 micrograms twice daily and 40 mg per day oral prednisolone on lung function, symptoms and bronchial hyperresponsiveness in patients with non-asthmatic chronic airflow obstruction. Thorax 1993;48(4):309-16.
85. Wojtczak HA, Kerby GS, Wagener JS, Copenhaver SC, Gotlin RW, Riches DW, et al. Beclomethasone dipropionate reduced airway inflammation without adrenal suppression in young children with cystic fibrosis: a pilot study. Pediatric Pulmonology 2001;32(4):293-302.
86. Zhang X, Moilanen E, Kankaanranta H. Beclomethasone, budesonide and fluticasone propionate inhibit human neutrophil apoptosis. European Journal of Pharmacology 2001;431(3):365-71.
87. Balfour-Lynn I, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews 2000, Issue 1. [DOI: 10.1002/14651858.CD001915]
88. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD001915.pub2]
89. Balfour-Lynn IM, Welch K. Inhaled corticosteroids for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 11. [DOI: 10.1002/14651858.CD001915.pub3]